145 related articles for article (PubMed ID: 32504998)
1. TJ-M2010-5, a novel MyD88 inhibitor, corrects R848-induced lupus-like immune disorders of B cells in vitro.
Zou Z; Du D; Miao Y; Yang Y; Xie Y; Li Z; Zhou L; Zhang L; Zhou P; Jiang F
Int Immunopharmacol; 2020 Aug; 85():106648. PubMed ID: 32504998
[TBL] [Abstract][Full Text] [Related]
2. Short-term use of MyD88 inhibitor TJ-M2010-5 prevents d-galactosamine/lipopolysaccharide-induced acute liver injury in mice.
Ding Z; Du D; Yang Y; Yang M; Miao Y; Zou Z; Zhang X; Li Z; Zhang X; Zhang L; Wang X; Zhao Y; Jiang J; Jiang F; Zhou P
Int Immunopharmacol; 2019 Feb; 67():356-365. PubMed ID: 30583234
[TBL] [Abstract][Full Text] [Related]
3. The MyD88 inhibitor TJ-M2010-2 suppresses proliferation, migration and invasion of breast cancer cells by regulating MyD88/GSK-3β and MyD88/NF-κB signalling pathways.
Liu JH; Chen C; Li ZY; Zou ZM; Gao DC; Zhang X; Kuang XW; Sun ZH; Zheng WJ; Zhou P; Sun SR
Exp Cell Res; 2020 Sep; 394(2):112157. PubMed ID: 32610185
[TBL] [Abstract][Full Text] [Related]
4. Targeting of MyD88 Homodimerization by Novel Synthetic Inhibitor TJ-M2010-5 in Preventing Colitis-Associated Colorectal Cancer.
Xie L; Jiang FC; Zhang LM; He WT; Liu JH; Li MQ; Zhang X; Xing S; Guo H; Zhou P
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26712311
[TBL] [Abstract][Full Text] [Related]
5. Short-term Pharmacological Inhibition of MyD88 Homodimerization by a Novel Inhibitor Promotes Robust Allograft Tolerance in Mouse Cardiac and Skin Transplantation.
Li C; Zhang LM; Zhang X; Huang X; Liu Y; Li MQ; Xing S; Yang T; Xie L; Jiang FC; Jiang HY; He WT; Zhou P
Transplantation; 2017 Feb; 101(2):284-293. PubMed ID: 27607533
[TBL] [Abstract][Full Text] [Related]
6. Beyond knockout: A novel homodimerization-targeting MyD88 inhibitor prevents and cures type 1 diabetes in NOD mice.
Zhang X; Xing S; Li M; Zhang L; Xie L; He W; Liu J; Chang S; Jiang F; Zhou P
Metabolism; 2016 Sep; 65(9):1267-77. PubMed ID: 27506734
[TBL] [Abstract][Full Text] [Related]
7. Modulating the conformation of the TIR domain by a neoteric MyD88 inhibitor leads to the separation of GVHD from GVT.
Xing S; Zhang X; Huang X; Xie L; Jiang F; Zhou P
Leuk Lymphoma; 2019 Jun; 60(6):1528-1539. PubMed ID: 30501537
[TBL] [Abstract][Full Text] [Related]
8. Heightened TLR7/9-Induced IL-10 and CXCL13 Production with Dysregulated NF-ҝB Activation in CD11c
Yim LY; Lau CS; Chan VS
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31546763
[TBL] [Abstract][Full Text] [Related]
9. R848 Is Involved in the Antibacterial Immune Response of Golden Pompano (
Zhou Y; Chen X; Cao Z; Li J; Long H; Wu Y; Zhang Z; Sun Y
Front Immunol; 2020; 11():617522. PubMed ID: 33537035
[TBL] [Abstract][Full Text] [Related]
10. Immune effects of R848: evidences that suggest an essential role of TLR7/8-induced, Myd88- and NF-κB-dependent signaling in the antiviral immunity of Japanese flounder (Paralichthys olivaceus).
Zhou ZX; Sun L
Dev Comp Immunol; 2015 Mar; 49(1):113-20. PubMed ID: 25475963
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological inhibition of MyD88 homodimerization counteracts renal ischemia reperfusion-induced progressive renal injury in vivo and in vitro.
Zhang LM; Liu JH; Xue CB; Li MQ; Xing S; Zhang X; He WT; Jiang FC; Lu X; Zhou P
Sci Rep; 2016 Jun; 6():26954. PubMed ID: 27246399
[TBL] [Abstract][Full Text] [Related]
12. A Novel Inhibitor of Homodimerization Targeting MyD88 Ameliorates Renal Interstitial Fibrosis by Counteracting TGF-β1-Induced EMT in Vivo and in Vitro.
Liu JH; He L; Zou ZM; Ding ZC; Zhang X; Wang H; Zhou P; Xie L; Xing S; Yi CZ
Kidney Blood Press Res; 2018; 43(5):1677-1687. PubMed ID: 30380557
[TBL] [Abstract][Full Text] [Related]
13. TJ-M2010-5, A self-developed MyD88 inhibitor, attenuates liver fibrosis by inhibiting the NF-κB pathway.
Xie Y; Du D; Zhang L; Yang Y; Zou Z; Li Z; Zhou L; Shang R; Zhou P
Chem Biol Interact; 2022 Feb; 354():109839. PubMed ID: 35101388
[TBL] [Abstract][Full Text] [Related]
14. Maintenance of autoantibody production in pristane-induced murine lupus.
Han S; Zhuang H; Xu Y; Lee P; Li Y; Wilson JC; Vidal O; Choi HS; Sun Y; Yang LJ; Reeves WH
Arthritis Res Ther; 2015 Dec; 17():384. PubMed ID: 26717913
[TBL] [Abstract][Full Text] [Related]
15. B cell autophagy mediates TLR7-dependent autoimmunity and inflammation.
Weindel CG; Richey LJ; Bolland S; Mehta AJ; Kearney JF; Huber BT
Autophagy; 2015; 11(7):1010-24. PubMed ID: 26120731
[TBL] [Abstract][Full Text] [Related]
16. Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells.
Wang L; Hu D; Xie B; Xie L
Invest New Drugs; 2022 Jun; 40(3):506-518. PubMed ID: 35089465
[TBL] [Abstract][Full Text] [Related]
17. TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus.
Lee PY; Kumagai Y; Li Y; Takeuchi O; Yoshida H; Weinstein J; Kellner ES; Nacionales D; Barker T; Kelly-Scumpia K; van Rooijen N; Kumar H; Kawai T; Satoh M; Akira S; Reeves WH
J Exp Med; 2008 Dec; 205(13):2995-3006. PubMed ID: 19047436
[TBL] [Abstract][Full Text] [Related]
18. TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus.
Nickerson KM; Christensen SR; Shupe J; Kashgarian M; Kim D; Elkon K; Shlomchik MJ
J Immunol; 2010 Feb; 184(4):1840-8. PubMed ID: 20089701
[TBL] [Abstract][Full Text] [Related]
19. Treatment of a MyD88 inhibitor alleviates rejection and inflammation in xenotransplantation by inhibiting dendritic cells activation and trained immunity in macrophages.
Li Z; Zhao M; Yang Y; Zou Z; Zhang L; Jiang F; Du D; Zhou P
Int Immunopharmacol; 2024 Mar; 130():111664. PubMed ID: 38377850
[TBL] [Abstract][Full Text] [Related]
20. Dosage of X-linked Toll-like receptor 8 determines gender differences in the development of systemic lupus erythematosus.
Umiker BR; Andersson S; Fernandez L; Korgaokar P; Larbi A; Pilichowska M; Weinkauf CC; Wortis HH; Kearney JF; Imanishi-Kari T
Eur J Immunol; 2014 May; 44(5):1503-16. PubMed ID: 24500834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
